Omega Diagnostics Gp (ODX.L) Confirmation of detection of Omicron variant

VISITECT® COVID-19 antigen test performs with the same high accuracy on the Omicron variant

Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Global Health (CD4 and COVID-19) and Health and Nutrition products, has been notified by its technology partner Mologic Ltd (“Mologic”) that data from analysis on clinical samples, as well as in-silico analysis, show that the Mologic Covios® Ag lateral flow test, performs with the same high accuracy on the Omicron variant as it does with existing known variants.

This is the same test that is manufactured and sold for professional use by Omega as the VISITECT® COVID-19 antigen test.

Colin King, CEO, Omega Diagnostics, said: “We are very pleased be in a position to confirm that the VISITECT® COVID-19 antigen test is able to equally detect the Omicron variant, as well as other existing variants. We remain encouraged by emerging commercial opportunities for our VISITECT® COVID-19 Antigen test that we expect to be unlocked following relevant approval under CTDA regulations and CE-marking for home-use.”

Contacts:

Omega Diagnostics Group PLC

www.omegadx.com

Colin King, Chief Executive Officer

via Walbrook PR

Chris Lea, Chief Financial Officer


Linking Shareholders and Executives :Share Talk

If anyone reads this article found it useful, helpful? Then please subscribe www.share-talk.com or follow SHARE TALK on our Twitter page for future updates. Terms of Website Use All information is provided on an as-is basis. Where we allow Bloggers to publish articles on our platform please note these are not our opinions or views and we have no affiliation with the companies mentioned

Subscribe To Our Daily Update

Share via
Copy link
Malcare WordPress Security